Whitehawk Therapeutics (WHWK) director granted 38,040 stock options at $4.16 strike

Rhea-AI Filing Summary

Whitehawk Therapeutics director Emma Reeve received a stock option grant, giving her the right to buy 38,040 shares of common stock at an exercise price of $4.16 per share. The option was granted as a compensation award with no cash paid at grant.

The option expires on June 12, 2036. All 38,040 shares subject to the option vest 100% on the earlier of one year after the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting, as long as she continues as a service provider. Following this grant, she holds options covering 38,040 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reeve Emma

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 38,040 shares Exercise price: $4.16 per share Expiration date: June 12, 2036 +2 more

5 metrics

Option grant size 38,040 shares Stock Option (right to buy) underlying common stock

Exercise price $4.16 per share Conversion or exercise price of stock option

Expiration date June 12, 2036 Option expiration for the reported grant

Total options after grant 38,040 shares Total derivative shares following transaction, held directly

Vesting condition 100% cliff vesting Vests on earlier of one-year from grant or before next annual meeting, with continued service

Key Terms

Stock Option (right to buy), Equity Incentive Plan, Service Provider, vest, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Equity Incentive Plan financial

"Issuer's 2021 Equity Incentive Plan referenced in vesting footnote"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

vest financial

"one hundred percent (100%) of the shares subject to the option shall vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Whitehawk Therapeutics (WHWK) director Emma Reeve report on this Form 4?

Emma Reeve reported receiving a grant of stock options to acquire 38,040 shares of Whitehawk Therapeutics common stock. The award is a compensation-related grant, not an open-market purchase, and is structured as a derivative security giving future purchase rights at a fixed exercise price.

How many Whitehawk Therapeutics (WHWK) shares are covered by Emma Reeve’s new stock options?

The option grant covers 38,040 shares of Whitehawk Therapeutics common stock. These shares are the underlying securities that may be purchased upon exercise of the option, subject to vesting conditions and the long-dated expiration schedule specified in the award terms.

What is the exercise price and expiration date of Emma Reeve’s WHWK stock options?

The options have an exercise price of $4.16 per share and expire on June 12, 2036. This means Reeve can buy up to 38,040 shares at $4.16, once vested, any time before the expiration date, assuming continued eligibility under the plan.

How and when do Emma Reeve’s Whitehawk Therapeutics options vest?

All 38,040 option shares vest 100% on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting. Vesting requires that she continue as a service provider through the applicable vesting date.

Is Emma Reeve’s Form 4 transaction a market purchase of WHWK stock?

No, the filing shows a grant of stock options as compensation, coded as a grant, award, or other acquisition. No shares were bought in the open market, and the transaction price per option at grant was reported as $0.00 per share.

What is Emma Reeve’s derivative holdings in WHWK after this option grant?

After the transaction, Reeve directly holds stock options covering 38,040 shares of Whitehawk Therapeutics common stock. This reflects the full size of the reported award, as indicated by the total derivative shares following the transaction on the Form 4.